ORAL-B
26.5.2021 12:58:12 CEST | Business Wire | Press release
Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact chronic periodontal diseases have on wider systemic disease.
The brand is leading the way in innovation, technology and research to help protect oral health and educate about the important connection between oral and overall body health. As part of the year-long partnership, Oral-B and Scientific American Custom Media are releasing a series of content, including educational resources from leading medical and dental researchers that will help readers better understand the connections between oral health and whole body health.
Oral diseases are at crisis level as it is estimated that they affect nearly 3.5 billion people worldwidei and in the midst of a global health pandemic, it is more crucial than ever to safeguard not only your oral health but your whole-body health too.
Jeremy A. Abbate, VP & Publisher at Scientific American explains: “Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health. It’s proven that periodontitis increasingly poses a significant risk to the development and progression of multiple systemic conditions and gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”
While warning signs can be as small as bleeding gums or even tooth loss, they can lead to more severe conditions such as heightened pregnancy complications, cognitive loss, poor diabetes control, and increases the risk of cardiovascular disease.
SYSTEMIC SPREAD OF PLAQUE BACTERIA THROUGHOUT THE BODY
A healthy mouth has minimal plaque build-up, ensuring oral bacteria cannot multiply, cause cavities, gum deterioration or spread beyond the mouth. However, when plaque build-up is present around the gum line and between teeth, it shelters oral bacteria (including P.gingivalis) from your toothbrush and natural defences. This provides the perfect conditions for the bacteria to thrive and cause inflammation-causing toxins that are known to spread throughout the rest of the body.
The formation of gum disease begins when plaque containing millions of bacteria coats the teeth, accumulates undisturbed. Acid produced by the bacteria can erode tooth enamel causing cavities and irritate the gums and cause gingivitis which can progress into periodontitis – a more serious infection that can lead to tooth loss.
When oral conditions worsen, the hidden plaque bacteria can cause an inflammatory response in the periodontal tissues that sets off a chain reaction, spreading systemically through the body via the circulatory system to other parts of the body. These oral bacteria are also found to be transmitted via the lungs and gastrointestinal tract.
DISEASES IMPACTED BY GUM DISEASE
- Stroke – Periodontitis may increase the risk for stroke. A continuous flow of bacteria into the bloodstream from exacerbated gum sites can trigger inflammation, prompting plaque growth and leading to blood clots.ii
- Diabetes - There is a two-way relationship between diabetes and periodontitis, with more severe periodontal tissue destruction observed in diabetic populations , due to poorly controlled glucose levels.iii iv
- Heart disease - Patients with periodontal disease are at increased risk for cardiovascular disease. Chronic gum inflammation may cause bad bacteria and toxins to enter the bloodstream and circulate to plaque sites in arterial walls.v
- Pregnancy gingivitis - Pregnant women are at increased risk of gingivitis and pregnant women with periodontitis are at increased risk for adverse pregnancy outcomes , including pre-term birth, low birth weight babies, and pregnancy hypertension (pre-eclampsia).vi
- Dementia - Patients with Alzheimer’s Disease and cognitive function loss have a higher risk for developing poor oral hygiene and periodontal disease. The relationship is bi-directional , as periodontal bacteria can also infect the brain and play a direct role in the build-up of amyloid brain lesions, leading to Alzheimer’s disease.vii
MAINTAINING A HEALTHY MOUTH AND BODY
Oral-B, the No.1 Dentist Recommended Toothbrush Brand Worldwide, is on a mission to make the invisible connection between oral health and whole-body wellness visible and to empower people to take their health into their own hands.
Following a daily holistic Oral-B regimen can help with maintaining a happy, healthy mouth:
-
Electric Toothbrush with a Round-Head
Oral-B brushes are round for a reason, to adapt to each individual tooth and reach between the teeth. The Oral-B iO’s revolutionary technology removes 100% more plaque than a manual brush to give you that professional clean feeling every single day.
-
Stannous Fluoride Toothpaste
Stannous Fluoride (SnF2) helps to protect your gums against bacterial plaque.
-
Mouth Rinse
Mouth rinses containing bioavailable Cetylpyridinium Chloride (CPC) formulated at 0.07% helps to reduce plaque.
-
Interdental Cleaning
Plaque easily accumulates and hides between teeth where toothbrushing can’t reach. Regular cleaning between teeth helps to remove plaque and helps protect gums.
-
Regular Oral-Health Check-Ups
Partner with your dental professional regularly to prevent and detect signs of gum infection at its earliest stages.
Scientific American educational resources developed in partnership with Oral B can be found here.
####
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by Dr. Robert Hutson, a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Artificial Intelligencery®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
i Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)
ii Janket SJ, Baird AE, Chuang SK, Jones JA. Meta- analysis of periodontal disease and risk for coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:559-569
iii Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998;3:51-61
iv Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: A two-way relationship. Diabetologia 2012;55:21-31.
v Blaizot A, Vergenes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: Meta-analyseis of observational studies. Int Dent J 2009; 59(4):197-209
vi Daalderop LD,Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF. Periodontal disease and pregnancy outcomes: Overview of systematic reviews. JDR Clinl Transl Res 2018;3:10-27. | Manrique-Corredor EJ, Orozco-Beltran D, Lopez-Pineda A, Quesada JA, Gil-Guillen VF, Carratala-Munuera C. Maternal periodontitis and preterm birth: systematic review and meta-analysis. Community Dent Oral Epidemiol 2019;47:243-251. | Chambrone L, Guglielmetti MR, Pannati CM, Chambrone LA. Evidence grade associating periodontitis to preterm birth and/or low birth weight: I. A systematic review of prospective cohort studies. J Clin Periodontol 2011;38:795-808. | Wei BJ, Chen YJ, Wu B. Periodontal disease and risk of preeclampsia: A meta- analysis of observational studies. PLOS ONE 2013;8:1-6. | Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol. 2008;Jan:7-22
vii Savitt ED, Socransky SS. Distribution of certain subgingival microbial species in selected periodontal conditions. J Periodontal Res 1984, 19 (2): 111-123.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005558/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
